VI to receive 8,000 doses of 'less potent' COVID-19 vaccines from UK next month
According to the press release, the VI will be receiving the vaccine developed by Oxford University and AstraZeneca, which was given regulatory approval by the UK Medicines and Healthcare products Regulatory Agency on December 30, 2020, after a rigorous, detailed scientific review by medical experts.
It said the vaccine has already been rolled out to thousands of individuals across the UK and is favoured for its more simple storage requirements compared to other vaccines.
Local Gov't will manage distribution
The Governor's Office said the Government of the Virgin Islands will be responsible for managing the rollout and distribution of the vaccine in the territory, and health officials are working on plans how to most effectively do this following a visit from Public Health England to discuss plans in December.
"Current advice from the World Health Organisation and Public Health England states that as many people as possible should take the vaccine. It will be offered on a voluntary basis in BVI," the press release stated.
His Excellency Governor August J. U. Jaspert said: “This is a fantastic opportunity for BVI. As one of the first places in the region to receive the vaccine, this gives us the opportunity to make these islands one of the safest places to live and visit.”
He added, “it is a clear signal of the UK and BVI’s special partnership and I am thankful to the UK for this generous donation which comes at no cost to BVI. Our Health Services and public officials have been doing a fantastic job to fight COVID-19 and I hope the arrival of the vaccine from the UK will be an extra boost to help defeat the virus.”
Further doses of the vaccine will be provided to the VI by the UK as rollout plans develop, the Governor's Office stated.
The last COVID-19 update on January 7, 2021, showed the Virgin Islands as having 18 active COVID-19 cases.
How effective is vaccine from UK?
The UK now has three different COVID-19 vaccines in use to fight the pandemic; however, the vaccine by AstraZeneca is considered the less potent.
And according to Business Insider on January 8, 2021, there is a reason why AstraZeneca's two-shot vaccine is still missing from the US vaccine arsenal.
The vaccine was developed in partnership with the University of Oxford and was authorized for use across the UK since December 30, 2020, and it's also been cleared to go into arms in India, Mexico, Argentina, and several more countries.
Vaccine ‘less effective’
The FDA; however, is waiting for AstraZeneca to submit its vaccine paperwork, which may not be ready until the spring.
That data, according to Business Insider, came from a vaccine research trial which included more than 5,800 volunteers around the UK, South Africa, and Brazil.
“The results suggested that AstraZeneca's vaccine was 62% effective at preventing symptomatic COVID-19 infections when taken as two full-strength shots. That's a much lower potency than both Pfizer and Moderna's shots, which were each more than 90% effective in trials.”
‘Big mistake’ during trial!
Business Insider also reported that the AstraZeneca trial included at least one big mistake. A subset of trial participants under 55 years old were accidentally administered a half-dose first shot, followed by a full-strength second jab.
"That's a pretty serious error," Dr Cody Meissner, chief of pediatric infectious disease at Tufts Medical Center, and one of the vaccine experts on the FDA's advisory committee, told Insider.
It said those patients who had a less potent initial shot, followed by a full-strength booster actually appeared more protected from coronavirus infections, with efficacy surging to 90% in the subgroup. Experts were puzzled by that.
"I won't go to the point of saying that it's not biologically plausible, but it's a little bit odd," Meissner said.
"It generates a little bit of pause, and makes one eager to actually look at the data and see what they found and to understand it a little bit more carefully."
According to Business Insider, the FDA; however, hasn't been offered that data to review for an emergency use authorisation (EUA), which would be required for Americans to start getting vaccinated with the shot.
“Instead, AstraZeneca is going to wait for the results of a larger, US-based trial, where no half-doses are planned,” Insider stated.
Governor Jaspert has said the VI is one of the first places in the region to receive the AstraZeneca vaccine; however, with the vaccine proving to be less potent than the other two approved in the UK and the FDA in the US not approving it for use due to limited data, there may be some concerns about taking the shots by some in the Virgin Islands.
.png)
Follow Us On
50 Responses to “VI to receive 8,000 doses of 'less potent' COVID-19 vaccines from UK next month”
What is the governments position on the reopening to regulare business of the tourism industry. This is a major game changer and we need to know now the details so we can make an informed decision about taking the vaccine.
I look forward to this information being released.
Why don't you report that we don't have the capacity to store the other vaccines which require special freezers and that this vaccine can be stored using regular refrigeration methods.
They need to stop in with their public spin this is an insult to the people
Explains the differences in the 3 vaccines.
Because, even in a pandemic Pfizer and Moderna need to profit off of illness for the benefit of shareholders, you check?
Lastly, Pfizer and Moderna are the newer mRNA vaccines using modified genetics to prompt human bodies to generate immune response in the form of antibodies. This will be the first time the mRNA is being used to fight disease (source: https://www.health.harvard.edu/blog/why-are-mrna-vaccines-so-exciting-2020121021599). AstraZeneca is adenovirus-based; adenovirus vaccines have a much longer history particularly for respiratory diseases and are not as new as mRNA.
The confusion about efficacy arises from the issue with inadvertent half-dosage. The US is conducting a trial with AstraZeneca and should have the results of that trial by the end of January, so before the vaccine arrives on BVI shores in February. AstraZeneca was trialled with healthy participants aged between 18 and 55. Pfizer and Moderna looked primarily at the virus as a disease of older persons and so focused on the over 65s, that's why they're skittish. They're focusing on what's best for the US population. The BVI needs to look at OUR local population, including pulling in census data (see why it's good not to postpone censuses, folks?) and see whether to focus on vaccines for over 65s or for those between 18 and 55. Generally, populations in the global south skew younger, so I would be tempted to say that the more stable vaccine based on previously tested technology which doesn't require subzero storage to remain stable and effective and is relevant for more people in the population is the way forward.
But, hey, what do I know. I'll leave it up to the Ministry to decide.
Bermuda, Cayman already vaccinating themselves with the better one.
They have far better competent governors & it shows.
It’s a life and death matter now. When is this dreadful gus man leaving???